The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.
The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.
A user experienced hair thinning and increased shedding after starting a high-dose B-complex supplement while using Minoxidil and RU58841. They are seeking advice on whether others have had similar issues with high doses of Vitamin B3 and B5.
Mixing 1ml of topical Minoxidil and Pyrilutamide (2ml total) together in a container and applying immediately is being discussed. The concern is whether this method degrades or compromises the efficacy of either compound.
The conversation discusses the high prices of hair loss treatments, specifically cb-03-01 and KY19382. It also mentions the use of Minoxidil, finasteride, and RU58841.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
Minoxidil 0.5% MMP® showed better results in parietal-vertex regions for less advanced female pattern hair loss compared to Minoxidil 5%. MMP® with Minoxidil can improve the quality of life for these patients.
PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.
The conversation is about starting a hair loss treatment using a topical solution containing RU58841, Minoxidil, and Copper Peptides. The user plans to test the product and share updates on its effectiveness.
A male in his early 20s with CCCA (scarring alopecia) started treatment with Finasteride, Fluocinolone, and Doxycycline. Steroid injections were suggested but not yet done.
Combining minoxidil 5%, tazarotene 0.1% cream, and lumigan for hair loss treatment is discussed. The conversation focuses on the safety and effectiveness of using these treatments together.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
A 25-year-old shared their 3-month progress using a combination of 1mg finasteride and 5% minoxidil for hair loss. The images show noticeable improvement in hair density.
Treatments for hair loss, specifically the use of minoxidil, finasteride and RU58841. Replies to this post suggest that users should share relevant information publicly rather than through direct messages.
A 26-year-old male with grade 3 hair loss is using 2.5 mg oral minoxidil, 1 mg finasteride, 5% minoxidil, ketoconazole shampoo, and kLM d3. He plans to post progress pictures every 6 weeks and is seeking suggestions.
Male pattern baldness (MPB) may be an early warning sign for type 2 diabetes due to its association with insulin resistance. Treatments discussed include testosterone therapy and finasteride, which affects hormone levels related to hair loss and insulin sensitivity.
KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.
A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.
Bicalutamide is discussed as a treatment for hair loss, particularly in females, with some users cautioning against its use due to potential side effects. The conversation also mentions using finasteride and other anti-androgens, with some users recommending more traditional treatments like dutasteride.
A user ordered Alpha Plus from Anagenica, expecting it to contain specific percentages of Fin, Estradiol, Minoxidil, and CB0301. However, the received product's label showed different percentages, including a surprising 25% CB, leading the user to question its safety and accuracy.
A user shared their hair transformation over four months using daily 2.5mg oral minoxidil, every other day 1mg oral finasteride, weekly dermastamping, and daily scalp massages, with plans for a hair transplant. Another user suggested continuing the medication for a year before considering a transplant.
The user shared progress pictures showing improvement in hair loss after 4 months of using Minoxidil and plans to start Finasteride. They received advice to stay consistent and consider oral Minoxidil.
A new hair loss treatment called TDM-105795 is discussed as a potential replacement or add-on to Minoxidil. Users express hope for new effective treatments.
The conversation discusses the high cost of CB-03-01, a topical antiandrogen for hair loss, which is considered safe and remains localized upon application. It questions whether the expense is justified compared to the lower risks it poses relative to finasteride.
A 28-year-old male uses custom-compounded topical solutions with Minoxidil, Finasteride, and Tretinoin for hair loss maintenance. He seeks advice on sourcing similar solutions in Bangkok, Thailand, and whether a local prescription is needed.
A user shared their positive experience with hair regrowth after six months of using minoxidil and finasteride, reporting no side effects. They showed progress photos and expressed hope for full restoration of their hair.
The user has been using topical minoxidil for over a year and added kx826/pyrilutamide to improve hair growth, avoiding finasteride due to side effects like lowered libido and panic attacks. They report positive results with reduced shedding and healthier hair, particularly in areas previously unresponsive to minoxidil.